In business over 50 years, but feeling 21. Maybe it’s the Botox.
For over 50 years, we’ve provided comprehensive care for women through a variety of gynecological treatments — like our Mona Lisa Touch™ procedure — along with wellness exams and health screenings — plus aesthetic treatments, like Botox.
To schedule an appointment, call (901) 767-3810.
botic arm system, the procedure can result in such benefits as reduced pain, shorter hospitalization stays, more rapid recovery, and a more natural feeling knee. St. Francis also brought the first Mazor Renaissance spine robot to Memphis, allowing doctors to perform even complex surgeries safely and efficiently. Other specialty areas at this 41-year-old hospital are bariatric services (Center for Surgical Weight Loss), cancer care, and diabetes care, to name a few. Reaching out to patients in northeast Shelby County is St. Francis Hospital-Bartlett, which opened in June 2004. Though smaller than the Memphis facility, this hospital nonetheless meets the needs of residents in the area with 88 medical/surgical beds, 10 mother-baby suites, 16 orthopedic/spine beds, an ICU and NICU section, an outpatient imaging center, and more.
ST. JUDE CHILDREN’S RESEARCH HOSPITAL
A division of Women’s Care Center of Memphis, MPLLC
www.adamspatterson.com
ALWAYS THERE FOR YOU
U
Internal Medicine & Family Medicine
Cecilia Dowsing-Adams, MD
Sam Faleye, MD, FACP
Primehealth Medical Center, P.C. 6637 Summer Knoll Circle, Suite 101, Bartlett, TN 38134 Ph.901-372-5260 • Fx.901-386-8726 • www.primehealthclinic.com
T
reatment of acute lymphoblastic leukemia (ALL), the most common childhood cancer, was one of the greatest cancer success stories of the twentieth century. Because of that treatment, today, 94 percent of St. Jude Children’s Research Hospital patients diagnosed with ALL will be alive in five years. But over a quarter of young adults with the most typical form of ALL still suffer from a newly identified subtype with a poor prognosis called Philadelphia chromosome-like ALL (Ph-like ALL), and often do not respond to treatment. Now, that may change. New research, led by St. Jude investigators, indicates the subtype is more prevalent with age and that patients with the subtype may benefit from drugs widely used to treat adult leukemia patients. Using genome sequencing, researchers also discovered the different genetic changes that drive the development of the disease. “There are multiple new genetic changes we’ve identified, but at the end of the day they activate only a limited number of cell growth pathways,” says Dr. Charles Mullighan, an associate member of the St. Jude Department of Pathology. “Those cell growth pathways can be inhibited with drugs we already have available. One, tyrosine kinase inhibitor (TKI), is widely used for other types of leukemia.” St. Jude investigators worked together with the Children’s Oncology Group, a national consortium of investigators that treat childhood cancer to identify the subtype. “I think we are justifiably proud that we were able to identify it and move to clinical trial in such a short period of
104 • M E M P H I S M A G A Z I N E . C O M • A U G U S T 2 0 1 5
096_MM08_2015_Medical.indd 104
7/22/15 2:30 PM